In the second part of this review and after having focused on one specific lymphoma subtype, which is the prototype for immunomodulative cancer, we will have a closer look at the various mechanisms touched in the previous sections, namely, PD1/PDL1, CTLA4/B7, HLA-G, CD58 and B2M, CD70, and CD27 as well as EBV. This evidence concerns the gene B2M and cancer.